Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
42 authors.
Marco FornaroDepartment of Precision and Regenerative Medicine and Ionian Area, Rheumatology Unit, University of Bari, Bari, Italy.ORCID 0000-0003-1716-7432
Vincenzo VeneritoDepartment of Precision and Regenerative Medicine and Ionian Area, Rheumatology Unit, University of Bari, Bari, Italy.ORCID 0000-0002-2573-5930
Maria Rosa PellicoDepartment of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy.ORCID 0009-0004-1921-7370
Florenzo IannoneDepartment of Precision and Regenerative Medicine and Ionian Area, Rheumatology Unit, University of Bari, Bari, Italy.ORCID 0000-0003-0474-5344
Mrudula JoshiByramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.ORCID 0000-0001-7312-351X
Yi-Ming ChenDivision of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.ORCID 0000-0001-7593-3065
Ai Lyn TanNIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK.ORCID 0000-0002-9158-7243
Samuel Katsuyuki ShinjoDivision of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.ORCID 0000-0002-3682-4517
Leonardo Santos HoffSchool of Medicine, Universidade Potiguar (UnP), Brazil.ORCID 0000-0002-2083-4796
Esha KadamSeth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, Maharashtra, India.ORCID 0000-0002-8739-4502
Tsvetelina VelikovaMedical Faculty, Sofia University St Kliment Ohridski, Sofia, Bulgaria.ORCID 0000-0002-0593-1272
A T M Tanveer HasanDepartment of Rheumatology, Green Life Medical College, Dhaka, Bangladesh.ORCID 0000-0002-5332-3319
Russka ShumnalievaDepartment of Rheumatology, Clinic of Rheumatology, University Hospital 'St Ivan Rilski', Medical University, Sofia, Bulgaria.ORCID 0000-0003-2321-6536
Marcin MilchertDepartment of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland.ORCID 0000-0002-0943-8768
Chou Luan TanRheumatology Unit, Department of Internal Medicine, Hospital Sultanah Bahiyah, Alor Setar, Malaysia.ORCID 0000-0002-9859-5385
Abraham Edgar Gracia-RamosDepartment of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Mexico City, Mexico.ORCID 0000-0003-1842-2554
Lorenzo CavagnaRheumatology Unit, Dipartimento di Medicine Interna e Terapia Medica, Università degli studi di Pavia, Pavia, Lombardy, Italy.ORCID 0000-0003-3292-1528
Binit VaidyaNational Center for Rheumatic Diseases (NCRD), Ratopul, Kathmandu, Nepal.ORCID 0000-0002-4840-8924
Masataka KuwanaDepartment of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.ORCID 0000-0001-8352-6136
Syahrul Sazliyana ShaharirFaculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.ORCID 0000-0002-9068-8114
Johannes KnitzaMedizinische Klinik 3-Rheumatologie und Immunologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.ORCID 0000-0001-9695-0657
Erick Adrian Zamora TehozolRheumatology, Medical Care & Research, Centro Medico Pensiones Hospital, Instituto Mexicano del Seguro Social Delegación Yucatán, Yucatán, Mexico.ORCID 0000-0002-7888-3961
Jorge Rojas SerranoRheumatologist and Clinical Investigator, Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.ORCID 0000-0001-6980-7898
Hussein HalabiDepartment of Internal Medicine, Section of rheumatology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.ORCID 0000-0002-5174-8292
Dzifa DeyRheumatology Unit, Department of Medicine and Therapeutics, University of Ghana Medical School, College of Health Sciences, Korle-Bu, Accra, Ghana.ORCID 0000-0002-3339-5112
Carlos Enrique Toro-GutiérrezGeneral Director, Reference Center for Osteoporosis, Rheumatology and Dermatology, Pontifica Universidad Javeriana Cali, Colombia.ORCID 0000-0002-6084-7049
Phonpen Akarawatcharangura GooDepartment of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand.
Carlo V Caballero-UribeDepartment of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombia.
Oliver DistlerDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0546-8310
Wanruchada KatchamartDivision of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-8952-5967
Jessica DayWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID 0000-0001-8528-4361
Ioannis ParodisDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-4875-5395
Elena NikiphorouCentre for Rheumatic Diseases, King's College London, London, UK.ORCID 0000-0001-6847-3726
Hector ChinoyDivision of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre The University of Manchester, Manchester, UK.ORCID 0000-0001-6492-1288
Vikas AgarwalDepartment of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.ORCID 0000-0002-4508-1233
Latika GuptaDivision of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre The University of Manchester, Manchester, UK.ORCID 0000-0003-2753-2990
CoVAD Study Group
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
objectiveThe presence of comorbidities can substantially affect patients' quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited.
methodsWe examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs) and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined basic multimorbidity (BM) as the presence of ≥2 non-rheumatic chronic conditions and complex multimorbidity (CM) as the presence of ≥3 non-rheumatic chronic conditions affecting ≥3 organ systems. Hierarchical clustering on principal components was performed for grouping.
resultsAmong the COVAD respondents, 1558 IIMs, 4591 oAIRDs and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (odds ratio [OR]: 1.62 vs oAIRDs and 2.95 vs HCs, P < 0.01), BM (OR: 1.66 vs oAIRDs and 3.52 vs HCs, P < 0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, P < 0.01) and mental health disorders (MHDs) (OR: 1.33 vs oAIRDs and 2.63 vs HCs, P < 0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all P < 0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores.
conclusionPatients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.
Indexed as
MultimorbidityMyositisQuality of LifeAdultAgedAutoimmune DiseasesCluster AnalysisComorbidityFemaleHumansMaleMiddle AgedPrevalenceRheumatic Diseasesautoinflammatory conditioncomorbiditymyositisobservational studiesquality of life
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset. · full record | OpenQuestion